# JW Therapeutics (Shanghai) Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/jw-therapeutics-shanghai-co

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.jwtherapeutics.com
- Total disclosed funding: $190M
- Latest round: Series B (Jun 9, 2020)
- Investors on record: 13

## About

JW Therapeutics engages in developing and commercializing innovative cell immunotherapy products focused on treating hematological malignancies and solid tumors, aiming to enhance patient care through advanced therapeutic solutions.Founded in 2016, JW Therapeutics (Shanghai) Co., Ltd. specializes in cell immunotherapy, with headquarters in Shanghai, China. The company was established by James Li, who has previous entrepreneurial experience. JW Therapeutics has raised HKD 2.330 billion in an IPO on November 3, 2020, selling 97.7 million shares at HKD 23.8 each, cumulatively raising HKD 2.330 billion across three funding deals.JW Therapeutics primarily focuses on developing, producing, and commercializing cell immunotherapy products for hematological malignancies, solid tumors, and autoimmune diseases. Their flagship CAR-T therapy, Ruiqiolun (commercially branded as Benoda®), received market approval from the National Medical Products Administration (NMPA) in September 2021. The company aims to meet critical therapeutic needs in oncology, serving diverse healthcare providers across China and looking to expand into other regions.JW Therapeutics generates revenue primarily through the sale of its proprietary CAR-T therapy products, which are distributed to certified healthcare institutions following comprehensive training and certification. The pricing of their products aligns with industry standards for advanced biopharmaceutical therapies. Their revenue stream is further supported by partnerships with medical institutions, facilitating broader adoption in the healthcare market.Looking ahead, JW Therapeutics plans to expand its portfolio with new products aimed at addressing additional oncology indications. The company's recent IPO funding of HKD 2.330 billion will support these initiatives. Furthermore, they aim to penetrate international markets in upcoming years, leveraging their proven technology and therapeutic offerings to enhance patient outcomes globally.

## Funding rounds

- Series B, Jun 9, 2020, $100M — ARCH Venture Partners, Hong Shan, Temasek Holdings, CPE Funds Management, Oriza Holdings, CR Capital, Juno Therapeutics, Inc., Mirae Asset Venture Investment, Loyal Valley Capital, Wuxi AppTec Group
- Series A, Mar 7, 2018, $90M — Hong Shan, Temasek Holdings, Oriza Holdings, Juno Therapeutics, Inc., Loyal Valley Capital, YuanMing Capital, Kington Capital, AVICT Global Holdings, Wuxi AppTec Group

## Investors

- Hong Shan — Series A, Series B
- Temasek Holdings — Series A, Series B
- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series A, Series B
- Juno Therapeutics, Inc. — Series A, Series B
- Loyal Valley Capital (https://capitalatlas.ai/funds/loyal-valley-capital) — Series A, Series B
- YuanMing Capital (https://capitalatlas.ai/funds/yuanming-capital) — Series A
- Kington Capital (https://capitalatlas.ai/funds/kington-capital) — Series A
- AVICT Global Holdings — Series A
- Wuxi AppTec Group — Series A, Series B
- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series B
- CPE Funds Management (https://capitalatlas.ai/funds/cpe-funds-management) — Series B
- CR Capital (https://capitalatlas.ai/funds/cr-capital) — Series B
- Mirae Asset Venture Investment (https://capitalatlas.ai/funds/mirae-asset-venture-investment) — Series B